The team will present its device and research findings at the American Chemical Society’s fall meeting, according to an Aug. 19 news release from the organization.
The device is called an electrochemical capillary-driven immunoassay and screens for biomarker proteins previously correlated with heart failure, Galectin-3 and S100A7, from a drop of saliva.
In collaboration with Griffith University in Queensland, Australia, researchers are set to test the device in a human trial at the university, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
